CN102175875B - 一种诊断结核病的检测试剂盒 - Google Patents
一种诊断结核病的检测试剂盒 Download PDFInfo
- Publication number
- CN102175875B CN102175875B CN 201110031070 CN201110031070A CN102175875B CN 102175875 B CN102175875 B CN 102175875B CN 201110031070 CN201110031070 CN 201110031070 CN 201110031070 A CN201110031070 A CN 201110031070A CN 102175875 B CN102175875 B CN 102175875B
- Authority
- CN
- China
- Prior art keywords
- tuberculosis
- diagnosis
- detection kit
- protein
- esat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000008827 tuberculosis Diseases 0.000 title claims abstract description 44
- 238000001514 detection method Methods 0.000 title claims abstract description 30
- 238000003745 diagnosis Methods 0.000 claims abstract description 34
- 102000036639 antigens Human genes 0.000 claims abstract description 21
- 108091007433 antigens Proteins 0.000 claims abstract description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 4
- 239000000090 biomarker Substances 0.000 claims description 5
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 claims description 3
- 101001057048 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) ESAT-6-like protein EsxB Proteins 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 16
- 102000004169 proteins and genes Human genes 0.000 abstract description 15
- 239000000427 antigen Substances 0.000 abstract description 13
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 238000013399 early diagnosis Methods 0.000 abstract description 4
- 230000003248 secreting effect Effects 0.000 abstract description 2
- 230000000890 antigenic effect Effects 0.000 abstract 4
- 108010075254 C-Peptide Proteins 0.000 abstract 2
- 241000186366 Mycobacterium bovis Species 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 238000000034 method Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 102100037850 Interferon gamma Human genes 0.000 description 12
- 108010074328 Interferon-gamma Proteins 0.000 description 12
- 241000193830 Bacillus <bacterium> Species 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 238000007789 sealing Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229960003130 interferon gamma Drugs 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 108700014461 ESAT-6-CFP10 fusion Proteins 0.000 description 3
- 241000186359 Mycobacterium Species 0.000 description 3
- 101100291912 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) mpb64 gene Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 102000040739 Secretory proteins Human genes 0.000 description 2
- 108091058545 Secretory proteins Proteins 0.000 description 2
- 229930003756 Vitamin B7 Natural products 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000000247 postprecipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960001005 tuberculin Drugs 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000011735 vitamin B7 Substances 0.000 description 2
- 235000011912 vitamin B7 Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 240000006995 Abutilon theophrasti Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 241000187486 Mycobacterium flavescens Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940070741 purified protein derivative of tuberculin Drugs 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000010907 stover Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000003805 vibration mixing Methods 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110031070 CN102175875B (zh) | 2011-01-27 | 2011-01-27 | 一种诊断结核病的检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110031070 CN102175875B (zh) | 2011-01-27 | 2011-01-27 | 一种诊断结核病的检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102175875A CN102175875A (zh) | 2011-09-07 |
CN102175875B true CN102175875B (zh) | 2013-06-05 |
Family
ID=44519080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110031070 Active CN102175875B (zh) | 2011-01-27 | 2011-01-27 | 一种诊断结核病的检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102175875B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103122033B (zh) * | 2011-11-21 | 2015-08-19 | 厦门大学 | 一种嵌合重组抗原及其用途 |
CN102608333B (zh) * | 2012-03-30 | 2013-06-05 | 中国科学院微生物研究所 | 一种结核诊断组合物及其应用 |
CN102660559B (zh) * | 2012-04-28 | 2013-07-03 | 吉林大学 | 一种结核分枝杆菌重组蛋白及其制备方法 |
CN104897893A (zh) * | 2015-06-10 | 2015-09-09 | 复旦大学附属华山医院 | 一种基于结核特异性il-31检测的诊断结核分枝杆菌感染的试剂盒 |
CN105131125B (zh) * | 2015-09-11 | 2019-04-30 | 广州迪澳医疗科技有限公司 | 一种用于诱导外周血单个核细胞产生结核相关细胞因子的融合蛋白 |
CN105524177A (zh) * | 2015-10-14 | 2016-04-27 | 中国人民解放军第三O九医院 | 结核分枝杆菌特异性融合蛋白及其编码基因与应用 |
CN107216373B (zh) * | 2017-03-29 | 2020-08-21 | 武汉海吉力生物科技有限公司 | 检测结核分枝杆菌感染的抗原多肽池及其应用 |
CN107141341B (zh) * | 2017-03-29 | 2020-08-28 | 武汉海吉力生物科技有限公司 | 检测结核分枝杆菌感染的抗原多肽池及应用 |
CN107011418B (zh) * | 2017-03-29 | 2020-08-25 | 武汉海吉力生物科技有限公司 | 检测结核分枝杆菌感染的抗原多肽池及其应用 |
CN107190075A (zh) * | 2017-06-27 | 2017-09-22 | 深圳优圣康医学检验所有限公司 | 用于mRNA检测的试剂及用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2360926C1 (ru) * | 2008-03-17 | 2009-07-10 | Всеволод Иванович Киселев | Гибридный белок cfp10-esat6, индуцирующий реакцию гиперчувствительности замедленного типа в отношении m.tuberculosis, кодирующая его химерная нуклеиновая кислота и рекомбинантный плазмидный экспрессирующий вектор, ее содержащий, способ получения гибридного белка и дозированная лекарственная форма для внутрикожной инъекции на его основе |
CN101538578A (zh) * | 2009-03-02 | 2009-09-23 | 华中农业大学 | 三基因融合的重组牛结核特异性抗原蛋白及制备方法 |
CN101735321A (zh) * | 2008-11-27 | 2010-06-16 | 上海荣盛生物药业有限公司 | 多肽组合物及其在结核病抗体检测中的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0716070D0 (en) * | 2007-08-17 | 2007-09-26 | Fusion Antibodies Ltd | Diagnostic method and kit |
-
2011
- 2011-01-27 CN CN 201110031070 patent/CN102175875B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2360926C1 (ru) * | 2008-03-17 | 2009-07-10 | Всеволод Иванович Киселев | Гибридный белок cfp10-esat6, индуцирующий реакцию гиперчувствительности замедленного типа в отношении m.tuberculosis, кодирующая его химерная нуклеиновая кислота и рекомбинантный плазмидный экспрессирующий вектор, ее содержащий, способ получения гибридного белка и дозированная лекарственная форма для внутрикожной инъекции на его основе |
CN101735321A (zh) * | 2008-11-27 | 2010-06-16 | 上海荣盛生物药业有限公司 | 多肽组合物及其在结核病抗体检测中的应用 |
CN101538578A (zh) * | 2009-03-02 | 2009-09-23 | 华中农业大学 | 三基因融合的重组牛结核特异性抗原蛋白及制备方法 |
Non-Patent Citations (9)
Title |
---|
H. Zhang et al..Recombinant Mycobacterium smegmatis Expressing an ESAT6-CFP10 Fusion Protein Induces Anti-Mycobacterial Immune Responses and Protects Against Mycobacterium tuberculosis Challenge in Mice.《Scandinavian Journal of Immunology》.2010,第72卷(第4期),349-357. |
Mycobacterium tuberculosis secretory proteins CFP-10, ESAT-6 and the CFP10:ESAT6 complex inhibit lipopolysaccharide-induced NF-κB transactivation by downregulation of reactive oxidative species (ROS) production;Niladri Ganguly et al.;《Immunology and Cell Biology》;20071002;第86卷;98-106 * |
NiladriGangulyetal..MycobacteriumtuberculosissecretoryproteinsCFP-10 ESAT-6 and the CFP10:ESAT6 complex inhibit lipopolysaccharide-induced NF-κB transactivation by downregulation of reactive oxidative species (ROS) production.《Immunology and Cell Biology》.2007 |
Recombinant Mycobacterium smegmatis Expressing an ESAT6-CFP10 Fusion Protein Induces Anti-Mycobacterial Immune Responses and Protects Against Mycobacterium tuberculosis Challenge in Mice;H. Zhang et al.;《Scandinavian Journal of Immunology》;20100612;第72卷(第4期);349-557 * |
WO20009024822A3A0 2009.02.26 |
娄培安 等.结核分枝杆菌分泌蛋白ESAT-6-CFP10 的融合表达及纯化.《热带病与寄生虫学》.2005,第3卷(第4期),196-200. |
娄培安 等.结核分枝杆菌特异性分泌抗原克隆和融合表达及抗原性鉴定.《中国校医》.2006,第20卷(第1期),全文. |
结核分枝杆菌分泌蛋白ESAT-6-CFP10 的融合表达及纯化;娄培安 等;《热带病与寄生虫学》;20051231;第3卷(第4期);196-200 * |
结核分枝杆菌特异性分泌抗原克隆和融合表达及抗原性鉴定;娄培安 等;《中国校医》;20060131;第20卷(第1期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN102175875A (zh) | 2011-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102175875B (zh) | 一种诊断结核病的检测试剂盒 | |
CN101221173A (zh) | ELISpot结核感染诊断试剂盒及其应用 | |
CN101289496B (zh) | 能激发机体抗结核杆菌的保护性免疫反应的抗原表位筛选方法及用途 | |
CN1888069A (zh) | 重组蛋白Rv3425及其在制备结核病试剂盒中的应用 | |
CN107011418B (zh) | 检测结核分枝杆菌感染的抗原多肽池及其应用 | |
CN101493454A (zh) | 结核病抗原特异的全血IFN-γ诊断试剂盒及其制作方法和应用方法 | |
CN101455847A (zh) | Esat6和cfp10蛋白在制备用于鉴定诊断结核病的药物中的应用 | |
CN103122033B (zh) | 一种嵌合重组抗原及其用途 | |
CN101492497A (zh) | 一种结核杆菌特异的重组蛋白的表达纯化方法及其应用 | |
CN102210860A (zh) | 一种结核分枝杆菌tb10.4-f1融合蛋白疫苗及制备方法 | |
CN102174114B (zh) | 全血INF-γ的特异性抗原蛋白、其制备方法及用途 | |
CN105131125A (zh) | 一种用于诱导外周血单个核细胞产生结核相关细胞因子的融合蛋白 | |
CN107141341B (zh) | 检测结核分枝杆菌感染的抗原多肽池及应用 | |
CN105567660A (zh) | 一种大肠杆菌重组表达结核分枝杆菌Rv2837c活性蛋白的方法及其应用 | |
CN105861520A (zh) | Rv3121蛋白在检测结核分枝杆菌感染中的应用 | |
CN103204936A (zh) | 沙门氏菌效应蛋白SopB的多克隆抗体的制备方法 | |
Mon et al. | Evaluation of cocktails with recombinant proteins of Mycobacterium bovis for a specific diagnosis of bovine tuberculosis | |
CN101533018B (zh) | 区分牛病原性和非病原性分枝杆菌感染的试剂盒及方法 | |
CN104004069A (zh) | 一种用于结核分枝杆菌感染检测、临床治疗疗效跟踪和抗结核疫苗开发的试剂及其应用 | |
CN106198971A (zh) | 结核分枝杆菌抗原蛋白Rv2351c的应用 | |
US10961284B2 (en) | Recombinant protein antigen of Orientia tsutsugamushi and vaccine composition using the same | |
CN101533017B (zh) | 重组融合蛋白介导的牛分枝杆菌感染检测试剂盒及方法 | |
CN104805063A (zh) | 结核分枝杆菌潜伏感染相关蛋白及其制备和应用 | |
CN101477125B (zh) | 诊断结核病的基于结核杆菌抗原性多肽的组合物 | |
CN104628834B (zh) | 一种结核感染t细胞免疫检测抗原及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Detection kit for diagnosing tuberculosis Effective date of registration: 20131231 Granted publication date: 20130605 Pledgee: Optics Valley Wuhan venture capital fund Co., Ltd. Pledgor: Wuhan Hygiea Bioscience Co., Ltd. Registration number: 2013420000025 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Detection kit for diagnosing tuberculosis Effective date of registration: 20131231 Granted publication date: 20130605 Pledgee: Optics Valley Wuhan venture capital fund Co., Ltd. Pledgor: Wuhan Hygiea Bioscience Co., Ltd. Registration number: 2013420000025 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20141219 Granted publication date: 20130605 Pledgee: Optics Valley Wuhan venture capital fund Co., Ltd. Pledgor: Wuhan Hygiea Bioscience Co., Ltd. Registration number: 2013420000025 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Yu Dehua Inventor after: Huang Jun Inventor after: Zhao Pingfeng Inventor after: Chen Yinfang Inventor before: Yu Dehua Inventor before: Huang Jun Inventor before: Zhao Pingfeng Inventor before: Chen Yinfang |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 430205 Building A82-1, Phase II Biomedical Park, 858 High-tech Avenue, Donghu Technology Development Zone, Wuhan City, Hubei Province Patentee after: Wuhan Hygiea Bioscience Co., Ltd. Address before: 430205 Room 408, Block B1, Guanggu Biological City, 666 High-tech Avenue, Donghu Development Zone, Wuhan City, Hubei Province Patentee before: Wuhan Hygiea Bioscience Co., Ltd. |